The deal spread in Globus Medical’s (NYSE:GMED) planned takeover of Nuvasive (NASDAQ:NUVA) widened slightly amid a report that the Federal Trade Commission is evaluating a path toward a potential lawsuit to challenge the deal. The spread widened to $3.31 from $2.87 on Wednesday.
The FTC has the deal on its radar for a possible lawsuit, according to traders, who cited a Capitol Forum story circulating on Thursday that mentions the deal as part of a larger piece about antitrust probes.
The report comes after medical device makers NuVasive (NUVA) and Globus Medical (GMED) announced an agreement in February to combine in an all-stock transaction, a deal that valued Nuvasive at about $3 billion at the time.
A Nuvasive/Globus deal may give doctors fewer operating options, according to some surgeons, Capitol Forum tweeted earlier this month.
Globus Medical (GMED) is scheduled to report Q2 results on Aug. 3.
More on Nuvasive/Globus Medical
Nuvasive/Globus Medical deal spread widens amid report FTC considering lawsuit
